Leading Chinese CRO Tigermed Joins Medidata Solutions Partner Program to Broaden Capabilities for Global and Local Clinical Tria

First Chinese CRO to Join Program to Use Leading EDC/CTMS Medidata Rave across Asia Pacific Market

NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that one of China's leading contract research organizations (CRO), Tigermed Consulting Co., Ltd., is the first Chinese CRO to become a Medidata Services Partner in the Medidata Partner Program. Tigermed will now offer a full suite of services supporting the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution.

"Partnering with Medidata Solutions to deliver Medidata Rave enables us to significantly increase our clinical development offerings to provide high-quality trials in a growing market with more complex studies"

Providing full clinical trials services, including biometrics services, across all phases of clinical trials, Shanghai-based Tigermed has extensive experience in oncology, endocrinology, CNS, virology and cardiology studies. Tigermed selected Medidata to support the company's move from paper processes to EDC and also leverage the company's broad global footprint to strengthen sponsor and site relationships. Offering Medidata Rave to its sponsor clients will help Tigermed better facilitate and enhance the accuracy of clinical trial data capture at every site, provide faster resolution of trial queries and speed trial execution time.

With 39 offices across China, including Hong Kong and Taiwan, Tigermed is focusing its early Medidata Rave usage on customers' Phase III trials with sites across that region as well as South Korea and Japan. Medidata Rave's multilingual capabilities, which enable investigators to enter data in the language of their choice, will help support Tigermed's global expansion.

"Partnering with Medidata Solutions to deliver Medidata Rave enables us to significantly increase our clinical development offerings to provide high-quality trials in a growing market with more complex studies," said Xiaoping Ye, chairman and CEO, Tigermed. "Additionally, Medidata's understanding of the Chinese market and its strong reputation across global sites, investigators and sponsors will strengthen our business development efforts as we grow our company."

Tigermed will also take advantage of Medidata's training programs to help staff build their knowledge base and quickly implement the solution across Asia. Tigermed anticipates the partnership's business impact will enhance staff satisfaction and enable them to grow the company's talent base.

"With access to a range of unique patient populations, the clinical trials market in China continues to expand at a rapid pace, and through this partnership, Tigermed is putting all the right tools and processes in place to position themselves for future growth," said Graham Bunn, vice president of partnerships and alliances, Medidata Solutions. "This partnership will bring opportunities for both Medidata and Tigermed to leverage each other's reputations and expertise to enhance clinical trial programs across Asia."

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then the program has grown to include about 30 partners, ranging from smaller clinical consultancies to large, global CROs.

About Tigermed

Tigermed Consulting Co., Ltd., is a leading Contract Research Organization (CRO) in China dedicated to providing regulatory affairs, Phase I-IV clinical trials, data management, biostatistics, medical translation and GCP training services for healthcare products. Since its inception in 2004, Tigermed has been committed to accelerating product development timelines while reducing R&D costs and risks, helping to bring the miracles of new products to market effectively.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
Contacts

Lois Paul & Partners
Susan McCarron, 617-986-5767
[email protected]

 

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.